Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/29824
Title: Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies
Authors: SOUZA, Fernando Henrique Carlos deMIOSSI, RenataMORAES, Julio Cesar Bertacini deBONFA, EloisaSHINJO, Samuel Katsuyuki
Citation: ADVANCES IN RHEUMATOLOGY, v.58, article ID 31, 6p, 2018
Abstract: Background: Interpretation of rituximab efficacy for refractory idiopathic inflammatory myopathies (IIM) is hampered by the absence of a uniform definition of refractory myositis and clinical response. Therefore, rigorous criteria of refractoriness, together with a homogenous definition of clinical improvement, were used to evaluate rituximab one-year response. Methods: A retrospective cohort study including 43 IIM (15 antisynthetase syndrome, 16 dermatomyositis, 12 polymyositis) was conducted. All patients had refractory disease (inadequate response to at least two immunosuppressives/immunomodulatories and no less than three months sequentially or concomitantly glucocorticoid tapering) criteria. Clinical/laboratory improvement at one-year was based on modified International Myositis Assessment & Clinical Studies Group (IMACS) core set measures. The patients received two infusions of rituximab (1 g each) at baseline, followed by repeated dose after 6 months. Baseline immunosuppressive therapy was maintained and glucocorticoid dose was tapered according to clinical/laboratory parameters. Results: Five patients had side effects at the first rituximab application and were excluded. Therefore, 38 out of 43 patients completed the one-year follow up. Almost 75% of the patients attained clinical and laboratory response after one-year. A significant reduction in median glucocorticoid dose (18.8 vs. 6.3 mg/day) was achieved and 42% patients were able to discontinue prednisone. In contrast, young individuals and patients with dysphagia had a tendency to be non-responders to rituximab. No severe infections were observed. Conclusion: This study provides convincing evidence that rituximab is an effective and safe therapy for refractory IIM.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/17
LIM/17 - Laboratório de Investigação em Reumatologia


Files in This Item:
File Description SizeFormat 
art_SOUZA_Favorable_rituximab_response_in_patients_with_refractory_idiopathic_2018.PDF
  Restricted Access
publishedVersion (English)554.48 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.